The role of laquinimod in modulation of the immune response in relapsing-remitting multiple sclerosis: Lessons from gene expression signatures

R. Zilkha-Falb; M. Gurevich; L. Hayardeny; A. Achiron

doi:10.1016/j.jneuroim.2015.04.007

The role of laquinimod in modulation of the immune response in relapsing-remitting multiple sclerosis: Lessons from gene expression signatures

R. Zilkha-Falb^*
, M. Gurevich
, L. Hayardeny
, A. Achiron

^*Corresponding author for this work

Clinical Departments

Sheba Medical Center at Tel Hashomer
Teva Pharmaceutical Industries Ltd.

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Laquinimod, is a potential oral immunomodulatory drug, for relapsing-remitting multiple sclerosis (RRMS).We analyzed the blood-transcriptional changes in RRMS patients (who participated in the ALLEGRO clinical trial) at one and six months after laquinimod treatment using gene expression microarrays.The molecular effects of laquinimod were enhanced by duration of treatment and showed down-regulation of inflammatory responses mainly via TGFb signaling, and of pro-inflammatory cytokines as well as of cellular movement, including adhesion, migration and leukocyte extravasation signaling.Our results demonstrate that laquinimod suppresses inflammation through down-regulation of inflammatory cytokines and arrest of leukocyte extravasation and thereby could attenuate disease activity in RRMS patients.

Original language	English
Pages (from-to)	11-16
Number of pages	6
Journal	Journal of Neuroimmunology
Volume	283
DOIs	https://doi.org/10.1016/j.jneuroim.2015.04.007
State	Published - 15 Jun 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Gene expression microarray
Laquinimod
Multiple sclerosis
Peripheral blood mononuclear cells

Access to Document

10.1016/j.jneuroim.2015.04.007

Cite this

@article{2c5628be137047c39b10e00a0f69d8bb,

title = "The role of laquinimod in modulation of the immune response in relapsing-remitting multiple sclerosis: Lessons from gene expression signatures",

abstract = "Laquinimod, is a potential oral immunomodulatory drug, for relapsing-remitting multiple sclerosis (RRMS).We analyzed the blood-transcriptional changes in RRMS patients (who participated in the ALLEGRO clinical trial) at one and six months after laquinimod treatment using gene expression microarrays.The molecular effects of laquinimod were enhanced by duration of treatment and showed down-regulation of inflammatory responses mainly via TGFb signaling, and of pro-inflammatory cytokines as well as of cellular movement, including adhesion, migration and leukocyte extravasation signaling.Our results demonstrate that laquinimod suppresses inflammation through down-regulation of inflammatory cytokines and arrest of leukocyte extravasation and thereby could attenuate disease activity in RRMS patients.",

keywords = "Gene expression microarray, Laquinimod, Multiple sclerosis, Peripheral blood mononuclear cells",

author = "R. Zilkha-Falb and M. Gurevich and L. Hayardeny and A. Achiron",

note = "Publisher Copyright: {\textcopyright} 2015 Elsevier B.V.",

year = "2015",

month = jun,

day = "15",

doi = "10.1016/j.jneuroim.2015.04.007",

language = "אנגלית",

volume = "283",

pages = "11--16",

journal = "Journal of Neuroimmunology",

issn = "0165-5728",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - The role of laquinimod in modulation of the immune response in relapsing-remitting multiple sclerosis

T2 - Lessons from gene expression signatures

AU - Zilkha-Falb, R.

AU - Gurevich, M.

AU - Hayardeny, L.

AU - Achiron, A.

PY - 2015/6/15

Y1 - 2015/6/15

N2 - Laquinimod, is a potential oral immunomodulatory drug, for relapsing-remitting multiple sclerosis (RRMS).We analyzed the blood-transcriptional changes in RRMS patients (who participated in the ALLEGRO clinical trial) at one and six months after laquinimod treatment using gene expression microarrays.The molecular effects of laquinimod were enhanced by duration of treatment and showed down-regulation of inflammatory responses mainly via TGFb signaling, and of pro-inflammatory cytokines as well as of cellular movement, including adhesion, migration and leukocyte extravasation signaling.Our results demonstrate that laquinimod suppresses inflammation through down-regulation of inflammatory cytokines and arrest of leukocyte extravasation and thereby could attenuate disease activity in RRMS patients.

AB - Laquinimod, is a potential oral immunomodulatory drug, for relapsing-remitting multiple sclerosis (RRMS).We analyzed the blood-transcriptional changes in RRMS patients (who participated in the ALLEGRO clinical trial) at one and six months after laquinimod treatment using gene expression microarrays.The molecular effects of laquinimod were enhanced by duration of treatment and showed down-regulation of inflammatory responses mainly via TGFb signaling, and of pro-inflammatory cytokines as well as of cellular movement, including adhesion, migration and leukocyte extravasation signaling.Our results demonstrate that laquinimod suppresses inflammation through down-regulation of inflammatory cytokines and arrest of leukocyte extravasation and thereby could attenuate disease activity in RRMS patients.

KW - Gene expression microarray

KW - Laquinimod

KW - Multiple sclerosis

KW - Peripheral blood mononuclear cells

UR - https://www.scopus.com/pages/publications/84929598546

U2 - 10.1016/j.jneuroim.2015.04.007

DO - 10.1016/j.jneuroim.2015.04.007

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 26004150

AN - SCOPUS:84929598546

SN - 0165-5728

VL - 283

SP - 11

EP - 16

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

ER -

The role of laquinimod in modulation of the immune response in relapsing-remitting multiple sclerosis: Lessons from gene expression signatures

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this